Animal models. All animal experiments were overseen and approved by the Animal Welfare Committee of Johns Hopkins University and were in compliance with University standards. Six-to 8-week old mice purchased from Harlan Breeders, IN, were used for tumor implantation studies. Balb/c mice were used to establish CT26 tumors and athymic nu/nu mice were used to establish HCT116 xenografts. A minimum of five animals were used for each experimental arm. Tumor cells (5 x 10 6 ) were injected subcutaneously into the right flank of each mouse and allowed to grow for ~10 days before randomization and treatment. Tumor volumes were calculated as length x width 2 x 0.5. C. novyi-NT spores were administered as a bolus tail vein injection of 300 million spores suspended in 0.2 ml phosphate buffered saline. As a control, one group of mice was treated with C. novyi-NT spores that had been thermally inactivated by incubation at 100°C for 12 hours. Inactivation was verified by plating of spores on Brucella Agar with 5% horse blood (Becton Dickinson, Sparks, MD). All drugs were administered 16 hours after spore injection via the tail vein. The doses of Doxil and doxorubicin were 10 mg/kg, whereas the doses of irinotecan and liposomal irinotecan were 25 mg/kg. In the experiment shown in fig. S3 , tumors were intratumorally injected with 100 µl of lipopolysaccharide (LPS) suspended in PBS (5mg/ml) or with PBS alone 24 hours prior to administering Doxil.
Pharmacokinetic Studies. HCT116 xenografts were established in athymic nu/nu mice and treated as described above. Tissue samples were harvested at various times after treatment, suspended in 70% ethanol, 0.3 N HCl and homogenized (Ultra-Turrax T25 Basic, IKA, NC) to extract doxorubicin. Following centrifugation, doxorubicin fluorescence (excitation at 470 nm, emission at 590 nm) in the supernatant was measured with a fluorescence plate reader (FluoStar Galaxy, BMG LabTech, GmbH). Concentrations were derived by reference to a doxorubicin standard curve.
Liposome-disrupting Activity. Samples were mixed with Doxil (100 µl sample + 5 µl Doxil in a 96-well plate or 50 µl sample + 2 µl DOXIL in a 384-well plate). The increase in fluorescence caused by the dequenching of released doxorubicin was measured at various time intervals thereafter using excitation at 470 nm and emission at 590 nm (S5) . All measurements were performed at 37°C in a fluorescence plate reader. A typical readout is shown in fig. S1 . Liposome-disrupting activity was defined as the maximum slope of the release curve.
Chemical Mutagenesis. All steps were performed in an anaerobic chamber (Type A, Coy Labs, Grass Lake, MI). C. novyi-NT spores were inoculated into 20 ml Bagadi Medium (S6) and incubated at 37°C for ~16 hours. When the cells were in log-phase (OD 600 = 0.6), 800 µl of the cell suspension was pulsed with a 20 µg/ml final concentration of MNNG for 20 minutes. One hundred µl of this suspension were transferred to a bottle containing 1 L Bagadi Medium and allowed to sporulate for 18 days. C. novyi-NT spores were purified as previously described (S1). Spores were plated on Brucella Blood Agar plates and a colony that lacked hemolytic activity was identified by a visual screen for lack of clearing. This clone (termed "Non-hemolytic") was found by DNA sequencing to possess a 971G>A transition within the phospholipase C gene (NT01CX0979) resulting in a mutation from a well-conserved glycine to a glutamine.
Biochemical Purification. C. novyi-NT spores were inoculated into 20 ml Bagadi Medium (S6) and incubated in an anaerobic chamber (Type A, Coy Labs, Grass Lake, MI) at 37°C for ~ 16 hours. One ml of this starter culture was used to inoculate 100 ml Bagadi Medium that had been pre-equilibrated in the anaerobic chamber. This culture was grown to late log phase then centrifuged at 5,000 g to remove bacteria. The supernatant was precipitated with 40% saturated ammonium sulfate at 4°C for 1 hour, then centrifuged at 5,000 g. After discarding the supernatant, the pellet was solubilized in TN buffer (100 mM Tris-HCl, pH 7.5, 0.1 M NaCl) and filter-sterilized. All subsequent chromatography was performed on an ÄKTA Purifier FPLC system (Amersham Biosciences, Piscataway, NJ). The filtered sample was loaded onto a mono Q 5/50 GL (Amersham) column equilibrated in TN buffer. The proteins were eluted with a linear gradient of ten column volumes formed from TN buffer and 100 mM Tris-HCl 7.5, 1 M NaCl. The fractions collected were assayed for doxorubicin releasing activity as described above. The two most active fractions from the mono Q column were pooled and loaded onto a HiLoad 16/60 Superdex 200 (Amersham) column equilibrated in 100 mM Tris-HCl pH 7.5, 0.5 M NaCl. The column was isocratically eluted with the same buffer over 1.5 column volumes. The fractions were assayed for doxorubicin disrupting activity as described above. Proteins in the two most active fractions were separated by electrophoresis through an SDS-polyacrylamide gel and silver-stained using a SilverSNAP Stain Kit II (Pierce, Rockford, IL). The single dominant band (~45 kD) was excised for analysis by LC/MS/MS. LC/MS/MS Peptide Analysis. The excised protein band was digested in-gel with trypsin and analyzed using procedures similar to those previously described (S7) . In brief, purified tryptic fragments were injected onto a 150 x 0.3 mm Vydac reverse phase column at 10 µL/min for 5 min in 5% buffer B using an Agilent 1100 Series Capillary-LC system. Buffers A (0.1% acetic acid) and B (99.9% acetonitrile and 0.1% acetic acid) were employed in the liquid chromatography (LC) step of the LC/MS/MS analysis. Peptides were eluted from the column with a 10-65% buffer B gradient over 90 min at a rate of 2 µL/min. Eluted peptides were detected by a LCQ DECA XP mass spectrometer (Thermo, MA), equipped with an electrospray ionization source, a low flow metal needle assembly operating in data dependent mode. The method consisted of two scan events, a full scan and a second data dependent MS/MS scan. The dynamic mass range of the full scan was set at 300 to 3000 m/z. The resulting MS/MS data dependent scan rejected known 'contaminant' masses of 371.0, 391.0, 445.0, 462.0, 1221.89, 1321.9, 1421.9, 1521.8, 1521.9, 1621.9, 1721 .9 and 1821.9 m/z. Other method settings included a default charge state set to 4, dynamic exclusion with repeat count set to 2, repeat duration 1 min, an exclusion list size of 25 and exclusion duration 3 min. All other method parameters were default values set by the Xcaliber software v.1.2 (Thermo, MA).
Cloning of oligohistidine-fusion proteins. The coding sequence of NT01CX2047, devoid of its N-terminal secretion signal (as predicted by SignalP 3.0) was PCR-amplified with Phusion Taq Polymerase (Finnzymes, Espoo, Finland) using forward primer 5'-TGCACCACCACCACCACCACAAAGAAAATCAAAAAGTATCACAAAATAATTATCCTATAAT ACTTTGTCATGG and reverse primer 5'-CTGACCGGTTTATTATTCAGTTACAGGAAGATTT CTAAGCATTTGAGCC. The (CAC) 6 sequence in the forward primer added six histidine residues at the N-terminus of the encoded protein. This PCR product was digested with Age I to create an insert with one sticky end. The cloning vector pCR2.1/T7-GFP (Invitrogen, Carlsbad, CA) was digested with Nde I, blunted with T4 DNA polymerase, then digested with Age I to create a single sticky end. The vector and insert were ligated to create pLip. The expected sequences of the inserts were verified by DNA sequencing.
Cloning of S127G and S127X variants. The pLip plasmid was digested with SnaB I to excise a 45 bp fragment containing the serine residue to be mutated. The pLip(S127G) plasmid was generated by blunt-end ligating the digested plasmid with a replacement 45 bp double-stranded oligonucleotide of sequence 5'-GTAAAGTTCATTTAATAGGACACGGTCAA GGTGGACAAACTATAC. The plasmid pLip(S127X) plasmid was generated in the same fashion using the double-stranded oligonucleotide 5'-GTAAAGTTCATTTAATAGGACA CTAATAAGGTGGACAAACTATAC. The targeted alterations (underlined above) and orientation of the inserts were verified by DNA sequencing.
Protein Expression. The expression vectors described above were transformed by heat shock into the Rosetta-gami(DE3)pLysS strain of E. coli (Novagen, Madison, WI). Three clones per expression construct were picked and each was cultured in 20 ml HyperBroth (AthenaES, Baltimore, MD) under antibiotic selection (100 µg/ml ampicillin + 34 µg/ml chloramphenicol) at room temperature. As a negative control, bacteria carrying the pLip plasmid were "cured" of their plasmid through growth in the absence of selective antibiotics. Loss of plasmid was verified by PCR. Expression was induced using IPTG for 1 hour, reaching an OD 600 ~0.2, after which the bacteria were pelleted by centrifugation and resuspended in 100 mM Tris-HCl, pH 7.5. Lysates were prepared by sonication in a Bioruptor sonicating bath (Diagenode, Belgium) and centrifugation at ~14,000 g was performed to remove insoluble matter. Western Blotting using an α-polyHistidine mouse mAb (R&D Systems, MN) was used to confirm the presence of the expected proteins.
Lipase Assay. EPC:Triolein:DPG in a molar ratio of 2:5:1 were mixed in chloroform and dried to a thin lipid film under rotary evaporation, then dried further under high vacuum for 2 hours. The film was hydrated with 100 mM glycine buffer, pH 9.5, 19 mM sodium deoxycholate to yield a final DPG concentration of 1 mM. This suspension was vortexed vigorously to form an emulsion for use as a substrate. Samples were mixed with this substrate (30 µl sample + 5 µl sample) in a 384-well plate. The increase in fluorescence caused by catalytic release of pyrenedecanoic acid was measured over 2 hours using excitation at 320 nm and emission at 405 nm (S8). All measurements were performed at 37°C in a FluoStar Galaxy fluorescence plate reader. Lipase Activity units were derived by reference to a Pseudomonas cepacia lipase standard curve. 1 unit (U) corresponds to the equivalent amount of P. cepacia lipase activity, which liberates 1 µmol per min of oleic acid from triolein.
Lipase Panel Experiment. Purified NT01CX2047 enzyme and nine other purified lipases were dissolved in 100 mM Tris-HCl, pH 7.5 to a concentration of 1 mg/ml. Fifty µl of Assay Buffer (100 mM Tris-HCl pH 7.5 + 0.125M NaCl) was pipetted into 384-well plates, followed by 2 µl of the relevant lipase and 1 µl of Doxil. Samples were assayed in duplicate for liposome-disrupting activity as described above.
Preparation of DPH-or Laurdan-labeled Liposomes. For DPH-labeled liposomes, a mixture of HEPC : Chol : DSPE-PEG 2000 : DPH at a molar ratio of 56.9:37.8:5.2:0.1 was solubilized in chloroform and dried to a thin film under rotary evaporation then further dried under vacuum for 2 hours. The films were hydrated with 10ml of Hydration Buffer (10 mM Tris-HCl, pH7.5, 0.1M NaCl) preheated to 65°C and sonicated continuously for 5 minutes using a Bioruptor bath sonicator (Diagenode, Belgium) to form Single Unilamellar Vesicles (SUVs) at 1mM lipid concentration. For Laurdan-labeled liposomes, the same procedure above was followed with two exceptions -(1) the molar composition was DPPC : Laurdan = 99.9 : 0.1 and (2) the Hydration Buffer was not preheated.
Fluorescence Polarization Spectroscopy. Various dilutions of purified NT01CX2047 in Assay Buffer (100 mM Tris-HCl pH 7.5 + 0.125M NaCl) were mixed with 5 µl of DPH-labeled liposomes in 384-well plates (55 µl total volume). Fluorescence polarization measurements (Ex:360nm/Em:430nm) were performed in triplicate using a DTX 880 Multimode Detector (Beckman Coulter). Anisotropies (r) were calculated as r = (Int ║ -Int ┴ ) / (Int ║ + 2 Int ┴ ) where Int represents the intensity of fluorescently emitted light either parallel (Int ║ ) or perpendicular (Int ┴ ) to the polarization of the incident light (S9). Bovine Serum Albumin (BSA) was used as a negative control for non-specific membrane-protein interactions. Decreased r values indicate a higher rate of tumbling of DPH within the lipid bilayer, implying an increase in membrane fluidity. The membrane-fluidizing agents ethanol and butanol were used as positive controls.
General Polarization Experiment. 45 µl Assay Buffer (100 mM Tris-HCl pH 7.5 + 0.125M NaCl), 5 µl of Laurdan-labeled liposomes and 5 µl of purified NT01CX2047 (0.12 mg/ml) were mixed in a 1.5 ml tube. Fluorometric measurements were performed using a ND-3300 Fluorospectrometer (Nanodrop, Wilmington, DE). Samples were excited at 365 nm and emission intensities recorded at 430 nm and 480 nm. General Polarization (GP) was calculated as (Int 430 -Int 480 )/(Int 430 + Int 480 ) where Int refers to emitted fluorescent intensities at the wavelengths in the subscripts (S9). Lower GP values are an indication of increased hydration within the lipid bilayer, implying physical perturbation of membrane integrity. BSA was used as a negative control for non-specific membrane-protein interactions.
RNA preparation. Vegetative bacteria were collected by centrifugation and homogenized by vortexing in RNAwiz buffer (RiboPure TM -Bacteria kit, Ambion, Austin, TX) containing 250 µL of Zirconia beads (Biospec, Bartlesville, OK) for 10 minutes at 4°C, followed by a 5-min break. This cycle was repeated 12 times to ensure disruption of the bacteria as assessed by phase contrast microscopy and RNA yield. RNA was purified with the RiboPure TM -Bacteria kit (Ambion) according to the manufacturer's instruction.
RNA was prepared from infected tumors by disrupting them in a glass homogenizer containing a 10-fold volume of the RNAwiz buffer. The tumors were homogenized on ice (50 strokes) and the homogenate aliquoted into 0.5-mL RNase-free tubes. The samples were then processed exactly as described above using a 12-cycle homogenization with Zirconia beads. RNA was quantified with a UV spectrophotometer (Spectra MAX Plus, Molecular Devices, Sunnyvale, CA) and separated through a precast 1.25% agarose gel (SigmaAldrich, St. Louis, MO) to examine its integrity. Purified RNA samples were stored at -80°C.
Reverse-transcription PCR (RT-PCR) and real-time PCR.
First-strand cDNA was synthesized from total RNA using random oligonucleotides as primers and the SuperScript™ First-Strand Synthesis System (Invitrogen). Real-time PCR was carried out with genespecific primers, Platinum Taq DNA polymerase, and SYBR green I (Invitrogen) in an iCycler (Bio-Rad, Hercules, CA) at 94°C for 20 sec, 57°C for 20 sec, and 70°C for 20 sec. Nucleotide sequences of primers used are as follows: Pyruvate kinase forward 5'-TGCAAACGACGGTGTTGTAT-3' and reverse 5'-TGGCTTCCACCATTTTCTTC-3'; Flagellin (fliC) forward 5'-GCTGGAAAAGCAATGGAAAA-3' and reverse 5'-AAGCTCCTTCAGCTGTTTGG-3'; Electron transfer flavoprotein subunit A (etfA) forward 5'-TCAAAGGCGTTTGGGTATTC-3' and reverse 5'-TGTCAGCTCCGTGTGCTAAT-3'; Liposomase forward 5'-CTGGGGTGGAAATGTTGACT-3' and reverse 5'-ATTGCCGTTTTCATCCTTTG-3'.
fig. S1. Live but not inactivated C. novyi-NT enhances the anti-tumor activity of Doxil in mice.
Mice bearing HCT116 xenografts were treated with various combinations of the indicated agents, and tumors and survival measured at the indicated times thereafter. In one group, spores were thermally inactivated as described in Supporting Online Material. The differences between C. novyi-NT plus Doxil and all other groups were significant (p<0.0133, log-rank test) in the survival curves. fig. S2 . C. novyi-NT and liposomal encapsulation are required for the enhancement of doxorubicin accumulation in tumors. (A) After HCT116 tumors reached ~300 mm 3 in size, LPS dissolved in phosphate-buffered saline (PBS) was injected into the tumors to induce inflammation, while PBS alone was injected into the tumors of a control group of animals. Twenty-four hours later, Doxil was administered intraveneously and the mice sacrificed four hours thereafter. Doxorubicin was extracted from the tumors and measured by fluorometry. Means and standard deviations from three mice per group are shown. (B) Doxorubicin or Doxil were administered to athymic nude mice bearing HCT116 tumors of ~300 mm 3 in size. One group of mice received C. novyi-NT spores in addition to doxorubicin. Mice were sacrificed at the indicated time points after treatment and doxorubicin was extracted from tissues and measured by fluorometry. Means and standard deviations from three mice per time point are shown. fig. S3 . Intratumoral distribution of doxorubicin after treatment with C. novyi-NT plus Doxil. Doxil was administered to athymic nude mice bearing HCT116 tumors of ~300 mm 3 in size. Another group of mice was intravenously injected with C.novyi-NT spores 16 hours prior to Doxil. Tumors were snap-frozen 16 hours after injection with Doxil and cryostat sections from the central regions examined using a fluorescence microscope (see Supporting Online Material). The fluorescence signal from doxorubicin in liposomes is quenched, while released doxorubicin emits fluorescence at 590 nm. Colocalization of the doxorubicin fluorescence and nuclear DNA, stained with DAPI, is observed in the tumors treated with C. novyi-NT spores. fig. S4 . Liposome-disrupting activity and levels of its mRNA expressed by C. novyi-NT. (A) Time course of doxorubicin release from Doxil in the presence of growth medium from C. novyi-NT cultures ("conditioned medium"). C. novyi-NT was grown until late log-phase and the medium cleared of cells via centrifugation. Significant liposome-disrupting activity was noted (red symbols) while no increase in fluorescence was observed in the indicated controls. (B) Liposome-disrupting activity as a function of growth time in culture. C. novyi-NT spores were inoculated in growth medium and the top half of the medium was harvested at the indicated time points. Absorbance at 600 nm was measured in the medium and the cells were pelleted. Liposome-disrupting activity in the supernatant was then assayed. Note that after reaching a growth plateau (~12 hr), the absorbance decreased as spores settled to the bottom of the flask. Means and standard deviations of data from at least two independent assays of liposome-disrupting activity are shown. Standard deviations are not visible when the bars representing them are smaller than the symbol of the corresponding data point. (C) Relative expression levels of C. novyi-NT genes in various growth conditions. RT-PCR analysis of C. novyi-NT RNA purified from cells in early log-phase, late log-phase, or from HCT116 tumors infected by C. novyi-NT. The fliC gene was expressed at similar levels during early and late log-phases and all expression values were normalized to that of fliC. Pyruvate kinase was expressed preferentially in early log-phase, while NT01CX2047 was preferentially expressed in late log-phase and at relatively high levels in infected tumors. fig. S5 . Liposome-disrupting activity of non-hemolytic mutants of C. novyi-NT. Following MNNG-mediated mutagenesis, a colony that lacked hemolytic activity was identified on blood agar. This clone ("Non-hemolytic) had a 971G>A transition within the phospholipase C gene (NT01CX0979) resulting in a mutation from a well-conserved glycine to a glutamine. (A) Both the non-hemolytic and WT clones were grown until late log-phase and the media cleared of cells via centrifugation. The growth-conditioned media of the non-hemolytic clone retained its liposome-disrupting activity. (B) Following precipitation of conditioned media with 40% saturated ammonium sulfate, ion exchange chromatography was performed. Liposomedisrupting activity was observed in identical fractions from both clones, indicating that this activity was not the result of phospholipase C activity or indeed of any other enzyme sufficient for hemolysis. fig. S6 . DNA coding sequence and amino acid sequence of the lipase encoded by NT01CX2047 (GenBank Accession number requested). fig. S7 . Expression of wild-type and mutant forms of C. novyi-NT NT01CX2047 in E. coli. Plasmids carrying the wt or mutant forms of the NT01CX2047 gene were introduced into E. coli. "Cured" bacteria represent those originally containing the wt gene and grown in the absence of selective antibiotics until the plasmid was lost. Cellular lysates from three independent clones of each bacterial strain were generated after induction of expression by IPTG. Immunoblotting of the lysates with an antibody to oligohistidine confirmed the presence of similar amounts of wt and mutant proteins in the lysates. , is a measure of membrane polarity, with lower values indicating greater access of polar molecules to the lipid bilayer. In addition to a negative control without additional protein, Bovine Serum Albumin (BSA) was used as a control for non-specific membrane-protein interactions. Means and standard deviations of data from triplicate readings are shown. fig. S9 . C. novyi-NT treatment enhances the anti-tumor activity of liposomal CPT-11 in mice. Mice bearing the indicated tumors were treated with various combinations of the indicated agents and tumors and survival measured at the indicated times thereafter. Means and standard errors of data calculated from at least five mice per group are shown. The differences between C. novyi-NT plus Doxil and the other groups were all significant (p<0.0003, log-rank test) in the survival curves. fig. S10 . Effect of C. novyi-NT treatment on animal weights. Means and standard deviations of animal weights from at least four mice per group are shown for the animal studies described in Figs. 1 and S9 . The weights of animals treated with liposomal drugs plus C. novyi-NT were not significantly different from those treated with the liposomal drugs alone.
